Taxotere, Docetaxel Newswire (Page 5)

Comprehensive Real-Time News Feed for Taxotere, Docetaxel (generic). (Page 5)

Results 81 - 100 of 917 in Taxotere, Docetaxel (generic)

  1. Verastem data compelling, says CantorRead the original story

    Jun 4, 2014 | Theflyonthewall.com

    Verastem data compelling, says Cantor After Verastem reported data from its Phase Ib combination study of defactinib in combination with docetaxel for the treatment of ovarian cancer, Cantor remains upbeat about the company's overall pipeline. It keeps a $22 price target and Buy rating on the stock.

    Comment?

  2. Cheap drug boosts prostate cancer survivalRead the original story w/Photo

    Jun 3, 2014 | WPTV Local News

    A cheap, decades-old chemotherapy drug extended life by more than a year when added to standard hormone therapy for men whose prostate cancer has widely spread, doctors reported Sunday.

    Comment?

  3. Lilly's CYRAMZA? (ramucirumab) Significantly Improves Overall...Read the original story

    Jun 2, 2014 | Applied Clinical Trials

    Data from the trial were published today in The Lancet and also presented at the American Society of Clinical Oncology Annual Meeting .

    Comment?

  4. Early chemo may boost prostate cancer survivalRead the original story w/Photo

    Jun 2, 2014 | CBS News

    Adding the chemotherapy drug docetaxel to standard hormone-depleting therapy may extend the lives of men with advanced prostate cancer , a new study finds.

    Comment?

  5. Common, hard-to-treat cancers: Potential new targeted therapiesRead the original story w/Photo

    Jun 2, 2014 | Science Daily

    Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted recently by researchers.

    Comment?

  6. Cheap drug greatly boosts prostate cancer survivalRead the original story

    Jun 1, 2014 | TwinCities

    A cheap, decades-old chemotherapy drug extended life by more than a year when added to standard hormone therapy for men whose prostate cancer has widely spread, doctors reported Sunday.

    Comment?

  7. New England Journal of Medicine Publishes Results from Phase 3...Read the original story

    Jun 1, 2014 | Applied Clinical Trials

    New England Journal of Medicine Publishes Results from Phase 3 PREVAIL Trial of Enzalutamide in Men with Chemotherapy-Naive Metastatic Prostate Cancer Progressing Despite Androgen Deprivation Therapy New England Journal of Medicine Publishes Results from Phase 3 PREVAIL Trial of Enzalutamide in Men with Chemotherapy-Naive Metastatic Prostate Cancer ... (more)

    Comment?

  8. Two new possible drug targets for triple negative breast cancerRead the original story

    May 27, 2014 | Science Daily

    The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment, report scientists.

    Comment?

  9. Fast TrackRead the original story w/Photo

    Oct 18, 2013 | WTVF Nashville

    Speeding the development and availability of drugs that treat serious diseases are in everyone's interest, especially when the drugs are the first available treatment.

    Comment?

  10. Better predictor of prostate cancer survival proposed by researchRead the original story w/Photo

    Mar 21, 2014 | Science Daily

    Measuring circulating tumor cells -- the cells that spread cancer through the body -- may be a better predictor of patient survival than the prostate-specific antigen, new research indicates.

    Comment?

  11. New Approach May Boost Survival From Advanced Prostate CancerRead the original story

    Jun 1, 2014 | HON

    Adding the chemotherapy drug docetaxel to standard hormone-depleting therapy may extend the lives of men with advanced prostate cancer, a new study finds.

    Comment?

  12. Lilly Drug Extends Survival in Advanced Lung Cancer PatientsRead the original story w/Photo

    May 31, 2014 | TheStreet.com

    Cyramza to standard chemotherapy reduced the risk of death by 14% compared to standard chemotherapy alone in lung cancer patients no longer responding to initial, or first-line, therapy, according to phase III study results announced Saturday at the American Society of Clinical Oncology annual meeting.

    Comment?

  13. Eli Lilly and Company's CYRAMZA (ramucirumab) Significantly...Read the original story w/Photo

    Jun 3, 2014 | BioSpace

    Eli Lilly and Company 's CYRAMZA Significantly Improves Overall Survival In Phase 3 Non-Small Cell Lung Cancer Study /PRNewswire/ -- Eli Lilly and Company today announced detailed results from REVEL, a global Phase III study of CYRAMZA in combination with chemotherapy in patients with second-line non-small cell lung cancer .

    Comment?

  14. New drugs may make a dent in lung, ovarian cancerRead the original story

    Jun 3, 2014 | Hispanic Business

    New drugs are making a dent against some hard-to-treat cancers, but some results raise fresh questions about whether the benefit is worth the cost.

    Comment?

  15. Drug combination extends survival by more than a year in metastatic prostate cancerRead the original story w/Photo

    Jun 1, 2014 | Science Daily

    Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists.

    Comment?

  16. Lilly cancer immunotherapeutic improves overall survivalRead the original story

    Jun 2, 2014 | Seeking Alpha

    In a Phase 3 trial , Eli Lilly's Cyramza in combination with chemotherapy extended overall survival in patients with second-line non-small cell lung cancer .

    Comment?

  17. Lilly's CYRAMZA(TM) (ramucirumab) Significantly Improves Overall ...Read the original story

    Jun 2, 2014 | Freshnews

    Eli Lilly and Company today announced detailed results from REVEL, a global Phase III study of CYRAMZA ) in combination with chemotherapy in patients with second-line non-small cell lung cancer .

    Comment?

  18. Men with metastatic prostate cancer may live longer with chemo firstRead the original story

    Jun 2, 2014 | Medical News Today

    In a clinical trial, men with newly diagnosed, metastatic, hormone-sensitive prostate cancer who received chemotherapy straight away alongside hormone-blocking therapy lived more than a year longer than men who followed the standard treatment - which is to wait until the tumors have become resistant to hormone therapy before receiving chemotherapy.

    Comment?

  19. Experimental Drug May Extend Lung Cancer Survival, Study SuggestsRead the original story w/Photo

    Jun 2, 2014 | MedicineNet

    A new "targeted" therapy might help extend the lives of patients with advanced lung cancer who have a relapse after their initial treatment, a clinical trial suggests.

    Comment?

  20. University of Texas Reports Findings in Docetaxel TherapyRead the original story

    May 28, 2014 | Hispanic Business

    Editor at Biotech Week -- Research findings on Drugs and Therapies are discussed in a new report.

    Comment?